VIVUS, Inc. (NASDAQ:VVUS)

CAPS Rating: 2 out of 5

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

Recs

0
Player Avatar SmartEquity (37.55) Submitted: 1/21/2013 9:09:52 AM : Outperform Start Price: $13.34 VVUS Score: -103.01

I believe the scrips will pick up as distribution is improved. The obesity patients will choose a riskier Qsymia over a safer less effective Belviq.

Featured Broker Partners


Advertisement